User login
Key clinical point: Cumulative androgen deprivation therapy (ADT) is associated with a significant risk for dementia in older men with prostate cancer.
Major finding: At a median follow-up of 7 years, 2.3% of patients were diagnosed with dementia. Cumulative ADT use showed a significant association with dementia (hazard ratio [HR], 2.02; P < .01). No significant association was seen between primary treatment type and onset of dementia in the patients who did not receive ADT (HR, 1.4; P = .14).
Study details: A retrospective study of 13,570 patients aged ≥50 years from the CaPSURE registry diagnosed with prostate cancer between 1995 and 2017.
Disclosures: This study was supported by the UCSF Goldberg-Benioff Program in Translational Cancer Biology. The authors reported no competing interests.
Source: Lonergan PE et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002335.
Key clinical point: Cumulative androgen deprivation therapy (ADT) is associated with a significant risk for dementia in older men with prostate cancer.
Major finding: At a median follow-up of 7 years, 2.3% of patients were diagnosed with dementia. Cumulative ADT use showed a significant association with dementia (hazard ratio [HR], 2.02; P < .01). No significant association was seen between primary treatment type and onset of dementia in the patients who did not receive ADT (HR, 1.4; P = .14).
Study details: A retrospective study of 13,570 patients aged ≥50 years from the CaPSURE registry diagnosed with prostate cancer between 1995 and 2017.
Disclosures: This study was supported by the UCSF Goldberg-Benioff Program in Translational Cancer Biology. The authors reported no competing interests.
Source: Lonergan PE et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002335.
Key clinical point: Cumulative androgen deprivation therapy (ADT) is associated with a significant risk for dementia in older men with prostate cancer.
Major finding: At a median follow-up of 7 years, 2.3% of patients were diagnosed with dementia. Cumulative ADT use showed a significant association with dementia (hazard ratio [HR], 2.02; P < .01). No significant association was seen between primary treatment type and onset of dementia in the patients who did not receive ADT (HR, 1.4; P = .14).
Study details: A retrospective study of 13,570 patients aged ≥50 years from the CaPSURE registry diagnosed with prostate cancer between 1995 and 2017.
Disclosures: This study was supported by the UCSF Goldberg-Benioff Program in Translational Cancer Biology. The authors reported no competing interests.
Source: Lonergan PE et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002335.